SEARCH

SEARCH BY CITATION

References

  • Abe, K., Hirai, M., Mizuno, K., Higashi, N., Sekimoto, T., Miki, T., Hirano, T. & Nakajima, K. (2001) The YXXQ motif in gp 130 is crucial for STAT3 phosphorylation at Ser727 through an H7-sensitive kinase pathway. Oncogene, 20, 34643474.
  • Adelaide, J., Perot, C., Gelsi-Boyer, V., Pautas, C., Murati, A., Copie-Bergman, C., Imbert, M., Chaffanet, M., Birnbaum, D. & Mozziconacci, M.J. (2006) A t(8;9) translocation with PCM1-JAK2 fusion in a patient with T-cell lymphoma. Leukemia, 20, 536537.
  • Antonioli, E., Guglielmelli, P., Pancrazzi, A., Bogani, C., Verrucci, M., Ponziani, V., Longo, G., Bosi, A. & Vannucchi, A.M. (2005) Clinical implications of the JAK2 V617F mutation in essential thrombocythemia. Leukemia, 19, 18471849.
  • Argetsinger, L.S., Kouadio, J.L., Steen, H., Stensballe, A., Jensen, O.N. & Carter-Su, C. (2004) Autophosphorylation of JAK2 on tyrosines 221 and 570 regulates its activity. Molecular and Cellular Biology, 24, 49554967.
  • Baxter, E.J., Scott, L.M., Campbell, P.J., East, C., Fourouclas, N., Swanton, S., Vassiliou, G.S., Bench, A.J., Boyd, E.M., Curtin, N., Scott, M.A., Erber, W.N. & Green, A.R. (2005) Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet, 365, 10541061.
  • Baylin, S.B. & Ohm, J.E. (2006) Epigenetic gene silencing in cancer – a mechanism for early oncogenic pathway addiction? Nature Reviews Cancer, 6, 107116.
  • Behrmann, I., Smyczek, T., Heinrich, P.C., Schmitz-Van de Leur, H., Komyod, W., Giese, B., Muller-Newen, G., Haan, S. & Haan, C. (2004) Janus kinase (Jak) subcellular localization revisited: the exclusive membrane localization of endogenous Janus kinase 1 by cytokine receptor interaction uncovers the Jak.receptor complex to be equivalent to a receptor tyrosine kinase. Journal of Biological Chemistry, 279, 3548635493.
  • Bellanne-Chantelot, C., Chaumarel, I., Labopin, M., Bellanger, F., Barbu, V., De Toma, C., Delhommeau, F., Casadevall, N., Vainchenker, W., Thomas, G. & Najman, A. (2006) Genetic and clinical implications of the Val617Phe JAK2 mutation in 72 families with myeloproliferative disorders. Blood, Blood First Edition Paper, Doi: 10.1182/blood-2005-12-4852.
  • Bellosillo, B., Besses, C., Florensa, L., Sole, F. & Serrano, S. (2006) JAK2 V617F mutation, PRV-1 overexpression and endogenous erythroid colony formation show different coexpression patterns among Ph-negative chronic myeloproliferative disorders. Leukemia, 20, 736737.
  • Bentz, M., Barth, T.F., Bruderlein, S., Bock, D., Schwerer, M.J., Baudis, M., Joos, S., Viardot, A., Feller, A.C., Muller-Hermelink, H.K., Lichter, P., Dohner, H. & Moller, P. (2001) Gain of chromosome arm 9p is characteristic of primary mediastinal B-cell lymphoma (MBL): comprehensive molecular cytogenetic analysis and presentation of a novel MBL cell line. Genes, Chromosomes and Cancer, 30, 393401.
  • Boggon, T.J., Li, Y., Manley, P.W. & Eck, M.J. (2005) Crystal structure of the Jak3 kinase domain in complex with a staurosporine analog. Blood, 106, 9961002.
  • Bourdeau, A., Dube, N. & Tremblay, M.L. (2005) Cytoplasmic protein tyrosine phosphatases, regulation and function: the roles of PTP1B and TC-PTP. Current Opinion in Cell Biology, 17, 203209.
  • Bousquet, M., Quelen, C., De Mas, V., Duchayne, E., Roquefeuil, B., Delsol, G., Laurent, G., Dastugue, N. & Brousset, P. (2005) The t(8;9)(p22;p24) translocation in atypical chronic myeloid leukaemia yields a new PCM1-JAK2 fusion gene. Oncogene, 24, 72487252.
  • Brakensiek, K., Langer, F., Schlegelberger, B., Kreipe, H. & Lehmann, U. (2005) Hypermethylation of the suppressor of cytokine signalling-1 (SOCS-1) in myelodysplastic syndrome. British Journal of Haematology, 130, 209217.
  • Bromberg, J. & Darnell, Jr, J.E. (2000) The role of STATs in transcriptional control and their impact on cellular function. Oncogene, 19, 24682473.
  • Bunting, K.D., Bradley, H.L., Hawley, T.S., Moriggl, R., Sorrentino, B.P. & Ihle, J.N. (2002) Reduced lymphomyeloid repopulating activity from adult bone marrow and fetal liver of mice lacking expression of STAT5. Blood, 99, 479487.
  • Campbell, P.J., Scott, L.M., Buck, G., Wheatley, K., East, C.L., Marsden, J.T., Duffy, A., Boyd, E.M., Bench, A.J., Scott, M.A., Vassiliou, G.S., Milligan, D.W., Smith, S.R., Erber, W.N., Bareford, D., Wilkins, B.S., Reilly, J.T., Harrison, C.N. & Green, A.R. (2005) Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet, 366, 19451953.
  • Campbell, P.J., Scott, L.M., Baxter, E.J., Bench, A.J., Green, A.R. & Erber, W.N. (2006a) Methods for the detection of the JAK2 V617F mutation in human myeloproliferative disorders. Methods in Molecular Medicine, 125, 253264.
  • Campbell, P.J., Griesshammer, M., Dohner, K., Dohner, H., Kusec, R., Hasselbalch, H.C., Larsen, T.S., Pallisgaard, N., Giraudier, S., Le Bousse-Kerdiles, M.C., Desterke, C., Guerton, B., Dupriez, B., Bordessoule, D., Fenaux, P., Kiladjian, J.J., Viallard, J.F., Briere, J., Harrison, C.N., Green, A.R. & Reilly, J.T. (2006b) V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis. Blood, 107, 20982100.
  • Cario, H., Goerttler, P.S., Steimle, C., Levine, R.L. & Pahl, H.L. (2005) The JAK2V617F mutation is acquired secondary to the predisposing alteration in familial polycythaemia vera. British Journal of Haematology, 130, 800801.
  • Carlesso, N., Frank, D.A. & Griffin, J.D. (1996) Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by Bcr/Abl. Journal of Experimental Medicine, 183, 811820.
  • Cavazzana-Calvo, M., Lagresle, C., Hacein-Bey-Abina, S. & Fischer, A. (2005) Gene therapy for severe combined immunodeficiency. Annual Review of Medicine, 56, 585602.
  • Changelian, P.S., Flanagan, M.E., Ball, D.J., Kent, C.R., Magnuson, K.S., Martin, W.H., Rizzuti, B.J., Sawyer, P.S., Perry, B.D., Brissette, W.H., McCurdy, S.P., Kudlacz, E.M., Conklyn, M.J., Elliott, E.A., Koslov, E.R., Fisher, M.B., Strelevitz, T.J., Yoon, K., Whipple, D.A., Sun, J., Munchhof, M.J., Doty, J.L., Casavant, J.M., Blumenkopf, T.A., Hines, M., Brown, M.F., Lillie, B.M., Subramanyam, C., Shang-Poa, C., Milici, A.J., Beckius, G.E., Moyer, J.D., Su, C., Woodworth, T.G., Gaweco, A.S., Beals, C.R., Littman, B.H., Fisher, D.A., Smith, J.F., Zagouras, P., Magna, H.A., Saltarelli, M.J., Johnson, K.S., Nelms, L.F., Des Etages, S.G., Hayes, L.S., Kawabata, T.T., Finco-Kent, D., Baker, D.L., Larson, M., Si, M.S., Paniagua, R., Higgins, J., Holm, B., Reitz, B., Zhou, Y.J., Morris, R.E., O'Shea, J.J. & Borie, D.C. (2003) Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor. Science, 302, 875878.
  • Chim, C.S., Fung, T.K., Cheung, W.C., Liang, R. & Kwong, Y.L. (2004a) SOCS1 and SHP1 hypermethylation in multiple myeloma: implications for epigenetic activation of the Jak/STAT pathway. Blood, 103, 46304635.
  • Chim, C.S., Wong, K.Y., Loong, F. & Srivastava, G. (2004b) SOCS1 and SHP1 hypermethylation in mantle cell lymphoma and follicular lymphoma: implications for epigenetic activation of the Jak/STAT pathway. Leukemia, 18, 356358.
  • Constantinescu, S.N., Keren, T., Socolovsky, M., Nam, H., Henis, Y.I. & Lodish, H.F. (2001) Ligand-independent oligomerization of cell-surface erythropoietin receptor is mediated by the transmembrane domain. Proceedings of the National Academy of Sciences of the United States of America, 98, 43794384.
  • Cools, J., DeAngelo, D.J., Gotlib, J., Stover, E.H., Legare, R.D., Cortes, J., Kutok, J., Clark, J., Galinsky, I., Griffin, J.D., Cross, N.C., Tefferi, A., Malone, J., Alam, R., Schrier, S.L., Schmid, J., Rose, M., Vandenberghe, P., Verhoef, G., Boogaerts, M., Wlodarska, I., Kantarjian, H., Marynen, P., Coutre, S.E., Stone, R. & Gilliland, D.G. (2003) A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. New England Journal of Medicine, 348, 12011214.
  • Dameshek, W. (1951) Some speculations on the myeloproliferative syndromes. Blood, 6, 372375.
  • De Keersmaecker, K. & Cools, J. (2006) Chronic myeloproliferative disorders: a tyrosine kinase tale. Leukemia, 20, 200205.
  • Decker, T. & Kovarik, P. (2000) Serine phosphorylation of STATs. Oncogene, 19, 26282637.
  • Demiroglu, A., Steer, E.J., Heath, C., Taylor, K., Bentley, M., Allen, S.L., Koduru, P., Brody, J.P., Hawson, G., Rodwell, R., Doody, M.L., Carnicero, F., Reiter, A., Goldman, J.M., Melo, J.V. & Cross, N.C. (2001) The t(8;22) in chronic myeloid leukemia fuses BCR to FGFR1: transforming activity and specific inhibition of FGFR1 fusion proteins. Blood, 98, 37783783.
  • Dupuis, S., Dargemont, C., Fieschi, C., Thomassin, N., Rosenzweig, S., Harris, J., Holland, S.M., Schreiber, R.D. & Casanova, J.L. (2001) Impairment of mycobacterial but not viral immunity by a germline human STAT1 mutation. Science, 293, 300303.
  • Dupuis, S., Jouanguy, E., Al-Hajjar, S., Fieschi, C., Al-Mohsen, I.Z., Al-Jumaah, S., Yang, K., Chapgier, A., Eidenschenk, C., Eid, P., Al Ghonaium, A., Tufenkeji, H., Frayha, H., Al-Gazlan, S., Al-Rayes, H., Schreiber, R.D., Gresser, I. & Casanova, J.L. (2003) Impaired response to interferon-alpha/beta and lethal viral disease in human STAT1 deficiency. Nature Genetics, 33, 388391.
  • Elliott, J. & Johnston, J.A. (2004) SOCS: role in inflammation, allergy and homeostasis. Trends in Immunology, 25, 434440.
  • Feener, E.P., Rosario, F., Dunn, S.L., Stancheva, Z. & Myers, Jr, M.G. (2004) Tyrosine phosphorylation of Jak2 in the JH2 domain inhibits cytokine signaling. Molecular and Cellular Biology, 24, 49684978.
  • Feng, J., Witthuhn, B.A., Matsuda, T., Kohlhuber, F., Kerr, I.M. & Ihle, J.N. (1997) Activation of Jak2 catalytic activity requires phosphorylation of Y1007 in the kinase activation loop. Molecular and Cellular Biology, 17, 24972501.
  • Firmbach-Kraft, I., Byers, M., Shows, T., Dalla-Favera, R. & Krolewski, J.J. (1990) Tyk2, prototype of a novel class of non-receptor tyrosine kinase genes. Oncogene, 5, 13291336.
  • Frohling, S., Lipka, D.B., Kayser, S., Scholl, C., Schlenk, R.F., Dohner, H., Gilliland, D.G., Levine, R.L. & Dohner, K. (2006) Rare occurrence of the JAK2 V617F mutation in AML subtypes M5, M6, and M7. Blood, 107, 12421243.
  • Galm, O., Yoshikawa, H., Esteller, M., Osieka, R. & Herman, J.G. (2003) SOCS-1, a negative regulator of cytokine signaling, is frequently silenced by methylation in multiple myeloma. Blood, 101, 27842788.
  • Gartsbein, M., Alt, A., Hashimoto, K., Nakajima, K., Kuroki, T. & Tennenbaum, T. (2006) The role of protein kinase C delta activation and STAT3 Ser727 phosphorylation in insulin-induced keratinocyte proliferation. Journal of Cell Science, 119, 470481.
  • Gauzzi, M.C., Barbieri, G., Richter, M.F., Uze, G., Ling, L., Fellous, M. & Pellegrini, S. (1997) The amino-terminal region of Tyk2 sustains the level of interferon alpha receptor 1, a component of the interferon alpha/beta receptor. Proceedings of the National Academy of Sciences of the United States of America, 94, 1183911844.
  • Goerttler, P.S., Steimle, C., Marz, E., Johansson, P.L., Andreasson, B., Griesshammer, M., Gisslinger, H., Heimpel, H. & Pahl, H.L. (2005) The Jak2V617F mutation, PRV-1 overexpression, and EEC formation define a similar cohort of MPD patients. Blood, 106, 28622864.
  • Grassmann, R., Aboud, M. & Jeang, K.T. (2005) Molecular mechanisms of cellular transformation by HTLV-1 Tax. Oncogene, 24, 59765985.
  • Griesinger, F., Hennig, H., Hillmer, F., Podleschny, M., Steffens, R., Pies, A., Wormann, B., Haase, D. & Bohlander, S.K. (2005) A BCR-JAK2 fusion gene as the result of a t(9;22)(p24;q11.2) translocation in a patient with a clinically typical chronic myeloid leukemia. Genes, Chromosomes and Cancer, 44, 329333.
  • Haan, C., Is'harc, H., Hermanns, H.M., Schmitz-Van De Leur, H., Kerr, I.M., Heinrich, P.C., Grotzinger, J. & Behrmann, I. (2001) Mapping of a region within the N terminus of Jak1 involved in cytokine receptor interaction. Journal of Biological Chemistry, 276, 3745137458.
  • Haan, C., Heinrich, P.C. & Behrmann, I. (2002) Structural requirements of the interleukin-6 signal transducer gp130 for its interaction with Janus kinase 1: the receptor is crucial for kinase activation. Biochemical Journal, 361, 105111.
  • Hannah, A.L. (2005) Kinases as drug discovery targets in hematologic malignancies. Current Molecular Medicine, 5, 625642.
  • Harrison, C.N., Gale, R.E., Machin, S.J. & Linch, D.C. (1999) A large proportion of patients with a diagnosis of essential thrombocythemia do not have a clonal disorder and may be at lower risk of thrombotic complications. Blood, 93, 417424.
  • Hayashida, K., Kitamura, T., Gorman, D.M., Arai, K., Yokota, T. & Miyajima, A. (1990) Molecular cloning of a second subunit of the receptor for human granulocyte-macrophage colony-stimulating factor (GM-CSF): reconstitution of a high-affinity GM-CSF receptor. Proceedings of the National Academy of Sciences of the United States of America, 87, 96559659.
  • He, B., You, L., Uematsu, K., Zang, K., Xu, Z., Lee, A.Y., Costello, J.F., McCormick, F. & Jablons, D.M. (2003) SOCS-3 is frequently silenced by hypermethylation and suppresses cell growth in human lung cancer. Proceedings of the National Academy of Sciences of the United States of America, 100, 1413314138.
  • Ten Hoeve, J., De Jesus Ibarra-Sanchez, M., Fu, Y., Zhu, W., Tremblay, M., David, M. & Shuai, K. (2002) Identification of a nuclear Stat1 protein tyrosine phosphatase. Molecular and Cellular Biology, 22, 56625668.
  • Horan, T., Wen, J., Narhi, L., Parker, V., Garcia, A., Arakawa, T. & Philo, J. (1996) Dimerization of the extracellular domain of granuloycte-colony stimulating factor receptor by ligand binding: a monovalent ligand induces 2:2 complexes. Biochemistry, 35, 48864896.
  • Hou, S.X., Zheng, Z., Chen, X. & Perrimon, N. (2002) The Jak/STAT pathway in model organisms: emerging roles in cell movement. Developmental Cell, 3, 765778.
  • Huang, L.J., Constantinescu, S.N. & Lodish, H.F. (2001) The N-terminal domain of Janus kinase 2 is required for Golgi processing and cell surface expression of erythropoietin receptor. Molecular Cell, 8, 13271338.
  • Ihle, J.N. (2001) The Stat family in cytokine signaling. Current Opinion in Cell Biology, 13, 211217.
  • Ihle, J.N., Witthuhn, B.A., Quelle, F.W., Yamamoto, K. & Silvennoinen, O. (1995) Signaling through the hematopoietic cytokine receptors. Annual Review of Immunology, 13, 369398.
  • Ihle, J.N., Thierfelder, W., Teglund, S., Stravapodis, D., Wang, D., Feng, J. & Parganas, E. (1998) Signaling by the cytokine receptor superfamily. Annals of the New York Academy of Sciences, 865, 19.
  • Ilangumaran, S., Ramanathan, S. & Rottapel, R. (2004) Regulation of the immune system by SOCS family adaptor proteins. Seminars in Immunology, 16, 351365.
  • Ingram, W., Lea, N.C., Cervera, J., Germing, U., Fenaux, P., Cassinat, B., Kiladjian, J.J., Varkonyi, J., Antunovic, P., Westwood, N.B., Arno, M.J., Mohamedali, A., Gaken, J., Kontou, T., Czepulkowski, B.H., Twine, N.A., Tamaska, J., Csomer, J., Benedek, S., Gattermann, N., Zipperer, E., Giagounidis, A., Garcia-Casado, Z., Sanz, G. & Mufti, G.J. (2006) The JAK2 V617F mutation identifies a subgroup of MDS patients with isolated deletion 5q and a proliferative bone marrow. Leukemia, advance online publication, April 13, 2006; Doi: 10.1038/sj.leu.240421.
  • Irie-Sasaki, J., Sasaki, T., Matsumoto, W., Opavsky, A., Cheng, M., Welstead, G., Griffiths, E., Krawczyk, C., Richardson, C.D., Aitken, K., Iscove, N., Koretzky, G., Johnson, P., Liu, P., Rothstein, D.M. & Penninger, J.M. (2001) CD45 is a JAK phosphatase and negatively regulates cytokine receptor signalling. Nature, 409, 349354.
  • Irie-Sasaki, J., Sasaki, T. & Penninger, J.M. (2003) CD45 regulated signaling pathways. Current Topics in Medicinal Chemistry, 3, 783796.
  • Jain, N., Zhang, T., Fong, S.L., Lim, C.P. & Cao, X. (1998) Repression of Stat3 activity by activation of mitogen-activated protein kinase (MAPK). Oncogene, 17, 31573167.
  • Jain, N., Zhang, T., Kee, W.H., Li, W. & Cao, X. (1999) Protein kinase C delta associates with and phosphorylates Stat3 in an interleukin-6-dependent manner. Journal of Biological Chemistry, 274, 2439224400.
  • James, C., Ugo, V., Le Couedic, J.P., Staerk, J., Delhommeau, F., Lacout, C., Garcon, L., Raslova, H., Berger, R., Bennaceur-Griscelli, A., Villeval, J.L., Constantinescu, S.N., Casadevall, N. & Vainchenker, W. (2005) A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature, 434, 11441148.
  • James, C., Delhommeau, F., Marzac, C., Teyssandier, I., Couedic, J.P., Giraudier, S., Roy, L., Saulnier, P., Lacroix, L., Maury, S., Tulliez, M., Vainchenker, W., Ugo, V. & Casadevall, N. (2006) Detection of JAK2 V617F as a first intention diagnostic test for erythrocytosis. Leukemia, 20, 350353.
  • Jamieson, C.H., Gotlib, J., Durocher, J.A., Chao, M.P., Mariappan, M.R., Lay, M., Jones, C., Zehnder, J.L., Lilleberg, S.L. & Weissman, I.L. (2006) The JAK2 V617F mutation occurs in hematopoietic stem cells in polycythemia vera and predisposes toward erythroid differentiation. Proceedings of the National Academy of Sciences of the United States of America, 103, 62246229.
  • Jelinek, J., Oki, Y., Gharibyan, V., Bueso-Ramos, C., Prchal, J.T., Verstovsek, S., Beran, M., Estey, E., Kantarjian, H.M. & Issa, J.P. (2005) JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia. Blood, 106, 33703373.
  • Johan, M.F., Bowen, D.T., Frew, M.E., Goodeve, A.C. & Reilly, J.T. (2005a) Aberrant methylation of the negative regulators RASSFIA, SHP-1 and SOCS-1 in myelodysplastic syndromes and acute myeloid leukaemia. British Journal of Haematology, 129, 6065.
  • Johan, M.F., Goodeve, A.C., Bowen, D.T., Frew, M.E. & Reilly, J.T. (2005b) JAK2 V617F mutation is uncommon in chronic myelomonocytic leukaemia. British Journal of Haematology, 130, 968.
  • Johnston, J.A., Kawamura, M., Kirken, R.A., Chen, Y.Q., Blake, T.B., Shibuya, K., Ortaldo, J.R., McVicar, D.W. & O'Shea, J.J. (1994) Phosphorylation and activation of the Jak-3 Janus kinase in response to interleukin-2. Nature, 370, 151153.
  • Jones, A.V., Kreil, S., Zoi, K., Waghorn, K., Curtis, C., Zhang, L., Score, J., Seear, R., Chase, A.J., Grand, F.H., White, H., Zoi, C., Loukopoulos, D., Terpos, E., Vervessou, E.C., Schultheis, B., Emig, M., Ernst, T., Lengfelder, E., Hehlmann, R., Hochhaus, A., Oscier, D., Silver, R.T., Reiter, A. & Cross, N.C. (2005) Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood, 106, 21622168.
  • Jones, A.V., Silver, R.T., Waghorn, K., Curtis, C., Kreil, S., Zoi, K., Hochhaus, A., Oscier, D., Metzgeroth, G., Lengfelder, E., Reiter, A., Chase, A.J. & Cross, N.C. (2006) Minimal molecular response in polycythemia vera patients treated with imatinib or interferon alpha. Blood, 107, 33393341.
  • Kaplan, M.H., Sun, Y.L., Hoey, T. & Grusby, M.J. (1996) Impaired IL-12 responses and enhanced development of Th2 cells in Stat4-deficient mice. Nature, 382, 174177.
  • Karaghiosoff, M., Neubauer, H., Lassnig, C., Kovarik, P., Schindler, H., Pircher, H., McCoy, B., Bogdan, C., Decker, T., Brem, G., Pfeffer, K. & Muller, M. (2000) Partial impairment of cytokine responses in Tyk2-deficient mice. Immunity, 13, 549560.
  • Karaghiosoff, M., Steinborn, R., Kovarik, P., Kriegshauser, G., Baccarini, M., Donabauer, B., Reichart, U., Kolbe, T., Bogdan, C., Leanderson, T., Levy, D., Decker, T. & Muller, M. (2003) Central role for type I interferons and Tyk2 in lipopolysaccharide-induced endotoxin shock. Nature Immunology, 4, 471477.
  • Kawamura, M., McVicar, D.W., Johnston, J.A., Blake, T.B., Chen, Y.Q., Lal, B.K., Lloyd, A.R., Kelvin, D.J., Staples, J.E., Ortaldo, J.R. & O'Shea, J.J. (1994) Molecular cloning of L-JAK, a Janus family protein-tyrosine kinase expressed in natural killer cells and activated leukocytes. Proceedings of the National Academy of Sciences of the United States of America, 91, 63746378.
  • Kiladjian, J.J., Elkassar, N., Cassinat, B., Hetet, G., Giraudier, S., Balitrand, N., Conejero, C., Briere, J., Fenaux, P., Chomienne, C. & Grandchamp, B. (2006a) Essential thrombocythemias without V617F JAK2 mutation are clonal hematopoietic stem cell disorders. Leukemia, 20, 11811183.
  • Kiladjian, J.J., Cassinat, B., Turlure, P., Cambier, N., Roussel, M., Bellucci, S., Menot, M.L., Massonnet, G., Dutel, J.L., Ghomari, K., Rousselot, P., Grange, M.J., Chait, Y., Vainchenker, W., Parquet, N., Abdelkader-Aljassem, L., Bernard, J.F., Rain, J.D., Chevret, S., Chomienne, C. & Fenaux, P. (2006b) High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a. Blood, Blood First Edition Paper, prepublished online May 18, 2006; Doi: 10.1182/blood-2006-03-009860.
  • Koyama, N., Koschmieder, S., Tyagi, S., Portero-Robles, I., Chromic, J., Myloch, S., Nurnberger, H., Rossmanith, T., Hofmann, W.K., Hoelzer, D. & Ottmann, O.G. (2006) Inhibition of phosphotyrosine phosphatase 1B causes resistance in BCR-ABL-positive leukemia cells to the ABL kinase inhibitor STI571. Clinical Cancer Research, 12, 20252031.
  • Kralovics, R., Guan, Y. & Prchal, J.T. (2002) Acquired uniparental disomy of chromosome 9p is a frequent stem cell defect in polycythemia vera. Experimental Hematology, 30, 229236.
  • Kralovics, R., Passamonti, F., Buser, A.S., Teo, S.S., Tiedt, R., Passweg, J.R., Tichelli, A., Cazzola, M. & Skoda, R.C. (2005) A gain-of-function mutation of JAK2 in myeloproliferative disorders. New England Journal of Medicine, 352, 17791790.
  • Kratz, C.P., Boll, S., Kontny, U., Schrappe, M., Niemeyer, C.M. & Stanulla, M. (2006) Mutational screen reveals a novel JAK2 mutation, L611S, in a child with acute lymphoblastic leukemia. Leukemia, 20, 381383.
  • Krolewski, J.J., Lee, R., Eddy, R., Shows, T.B. & Dalla-Favera, R. (1990) Identification and chromosomal mapping of new human tyrosine kinase genes. Oncogene, 5, 277282.
  • Kurzer, J.H., Argetsinger, L.S., Zhou, Y.J., Kouadio, J.L., O'Shea, J.J. & Carter-Su, C. (2004) Tyrosine 813 is a site of JAK2 autophosphorylation critical for activation of JAK2 by SH2-B beta. Molecular and Cellular Biology, 24, 45574570.
  • Lacout, C., Pisani, D.F., Tulliez, M., Moreau Gachelin, F., Vainchenker, W., Villeval, J.L. (2006) JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis. Blood, Doi: 10.1182/blood-2006–02–002030.
  • Lacronique, V., Boureux, A., Valle, V.D., Poirel, H., Quang, C.T., Mauchauffe, M., Berthou, C., Lessard, M., Berger, R., Ghysdael, J. & Bernard, O.A. (1997) A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia. Science, 278, 13091312.
  • LaMontagne, Jr, K.R., Flint, A.J., Franza, Jr, B.R., Pandergast, A.M. & Tonks, N.K. (1998) Protein tyrosine phosphatase 1B antagonizes signalling by oncoprotein tyrosine kinase p210 bcr-abl in vivo. Molecular and Cellular Biology, 18, 29652975.
  • Lasho, T.L., Mesa, R., Gilliland, D.G. & Tefferi, A. (2005) Mutation studies in CD3+, CD19+ and CD34+ cell fractions in myeloproliferative disorders with homozygous JAK2(V617F) in granulocytes. British Journal of Haematology, 130, 797799.
  • Lee, C.K., Raz, R., Gimeno, R., Gertner, R., Wistinghausen, B., Takeshita, K., DePinho, R.A. & Levy, D.E. (2002) STAT3 is a negative regulator of granulopoiesis but is not required for G-CSF-dependent differentiation. Immunity, 17, 6372.
  • Lee, J.W., Kim, Y.G., Soung, Y.H., Han, K.J., Kim, S.Y., Rhim, H.S., Min, W.S., Nam, S.W., Park, W.S., Lee, J.Y., Yoo, N.J. & Lee, S.H. (2006) The JAK2 V617F mutation in de novo acute myelogenous leukemias. Oncogene, 25, 14341436.
  • Lennartsson, J., Jelacic, T., Linnekin, D. & Shivakrupa, R. (2005) Normal and oncogenic forms of the receptor tyrosine kinase kit. Stem Cells, 23, 1643.
  • Leonard, W.J. & Lin, J.X. (2000) Cytokine receptor signaling pathways. Journal of Allergy and Clinical Immunology, 105, 877888.
  • Levine, R.L., Wadleigh, M., Cools, J., Ebert, B.L., Wernig, G., Huntly, B.J., Boggon, T.J., Wlodarska, I., Clark, J.J., Moore, S., Adelsperger, J., Koo, S., Lee, J.C., Gabriel, S., Mercher, T., D'Andrea, A., Frohling, S., Dohner, K., Marynen, P., Vandenberghe, P., Mesa, R.A., Tefferi, A., Griffin, J.D., Eck, M.J., Sellers, W.R., Meyerson, M., Golub, T.R., Lee, S.J. & Gilliland, D.G. (2005a) Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell, 7, 387397.
  • Levine, R.L., Loriaux, M., Huntly, B.J., Loh, M.L., Beran, M., Stoffregen, E., Berger, R., Clark, J.J., Willis, S.G., Nguyen, K.T., Flores, N.J., Estey, E., Gattermann, N., Armstrong, S., Look, A.T., Griffin, J.D., Bernard, O.A., Heinrich, M.C., Gilliland, D.G., Druker, B. & Deininger, M.W. (2005b) The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia. Blood, 106, 33773379.
  • Levine, R.L., Belisle, C., Wadleigh, M., Zahrieh, D., Lee, S., Chagnon, P., Gilliland, D.G. & Busque, L. (2006) X-inactivation-based clonality analysis and quantitative JAK2V617F assessment reveal a strong association between clonality and JAK2V617F in PV but not ET/MMM, and identifies a subset of JAK2V617F-negative ET and MMM patients with clonal hematopoiesis. Blood, 107, 41394141.
  • Levy, D.E. & Darnell, J.E. (2002) Stats: transcriptional control and biological impact. Nature Reviews Molecular Cell Biology, 3, 651662.
  • Lindauer, K., Loerting, T., Liedl, K.R. & Kroemer, R.T. (2001) Prediction of the structure of human Janus kinase 2 (JAK2) comprising the two carboxy-terminal domains reveals a mechanism for autoregulation. Protein Engineering, 14, 2737.
  • Liu, X., Robinson, G.W., Wagner, K.U., Garrett, L., Wynshaw-Boris, A. & Hennighausen, L. (1997) Stat5a is mandatory for adult mammary gland development and lactogenesis. Genes and Development, 11, 179186.
  • Livnah, O., Stura, E.A., Middleton, S.A., Johnson, D.L., Jolliffe, L.K. & Wilson, I.A. (1999) Crystallographic evidence for preformed dimers of erythropoietin receptor before ligand activation. Science, 283, 987990.
  • Lu, X., Levine, R., Tong, W., Wernig, G., Pikman, Y., Zarnegar, S., Gilliland, D.G. & Lodish, H. (2005) Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation. Proceedings of the National Academy of Sciences of the United States of America, 102, 1896218967.
  • Lucet, I.S., Fantino, E., Styles, M., Bamert, R., Patel, O., Broughton, S.E., Walter, M., Burns, C.J., Treutlein, H., Wilks, A.F. & Rossjohn, J. (2006) The structural basis of Janus kinase 2 inhibition by a potent and specific pan-Janus kinase inhibitor. Blood, 107, 176183.
  • Macchi, P., Villa, A., Giliani, S., Sacco, M.G., Frattini, A., Porta, F., Ugazio, A.G., Johnston, J.A., Candotti, F., O'Shea, J.J., Vezzoni, P., Notarangelo, L.D. (1995) Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID). Nature, 377, 6568.
  • Macdonald, D., Reiter, A. & Cross, N.C. (2002) The 8p11 myeloproliferative syndrome: a distinct clinical entity caused by constitutive activation of FGFR1. Acta Haematologica, 107, 101107.
  • Matsuda, T., Feng, J., Witthuhn, B.A., Sekine, Y. & Ihle, J.N. (2004) Determination of the transphosphorylation sites of Jak2 kinase. Biochemical and Biophysical Research Communications, 325, 586594.
  • Melzner, I. & Moller, P. (2003) Silencing of the SOCS-1 gene by CpG methylation? Blood, 102, 15541555; author reply 1555.
  • Melzner, I., Bucur, A.J., Bruderlein, S., Dorsch, K., Hasel, C., Barth, T.F., Leithauser, F. & Moller, P. (2005) Biallelic mutation of SOCS-1 impairs JAK2 degradation and sustains phospho-JAK2 action in the MedB-1 mediastinal lymphoma line. Blood, 105, 25352542.
  • Melzner, I., Weniger, M.A., Bucur, A.J., Bruderlein, S., Dorsch, K., Hasel, C., Leithauser, F., Ritz, O., Dyer, M.J., Barth, T.F. & Moller, P. (2006) Biallelic deletion within 16p13.13 including SOCS-1 in Karpas1106P mediastinal B-cell lymphoma line is associated with delayed degradation of JAK2 protein. International Journal of Cancer, 118, 19411944.
  • Meraz, M.A., White, J.M., Sheehan, K.C., Bach, E.A., Rodig, S.J., Dighe, A.S., Kaplan, D.H., Riley, J.K., Greenlund, A.C., Campbell, D., Carver-Moore, K., DuBois, R.N., Clark, R., Aguet, M. & Schreiber, R.D. (1996) Targeted disruption of the Stat1 gene in mice reveals unexpected physiologic specificity in the JAK-STAT signaling pathway. Cell, 84, 431442.
  • Mesa, R.A., Powell, H., Lasho, T., Dewald, G., McClure, R. & Tefferi, A. (2006a) JAK2(V617F) and leukemic transformation in myelofibrosis with myeloid metaplasia. Leukemia Research, Doi: 10.1016/j.leukres.2006.01.008.
  • Mesa, R.A., Powell, H., Lasho, T., DeWald, G.W., McClure, R. & Tefferi, A. (2006b) A longitudinal study of the JAK2(V617F) mutation in myelofibrosis with myeloid metaplasia: analysis at two time points. Haematologica, 91, 415416.
  • Migone, T.S., Lin, J.X., Cereseto, A., Mulloy, J.C., O'Shea, J.J., Franchini, G. & Leonard, W.J. (1995) Constitutively activated Jak-STAT pathway in T cells transformed with HTLV-I. Science, 269, 7981.
  • Mizuki, M., Fenski, R., Halfter, H., Matsumura, I., Schmidt, R., Muller, C., Gruning, W., Kratz-Albers, K., Serve, S., Steur, C., Buchner, T., Kienast, J., Kanakura, Y., Berdel, W.E. & Serve, H. (2000) Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways. Blood, 96, 39073914.
  • Moriggl, R., Sexl, V., Piekorz, R., Topham, D. & Ihle, J.N. (1999) Stat5 activation is uniquely associated with cytokine signaling in peripheral T cells. Immunity, 11, 225230.
  • Moutoussamy, S., Kelly, P.A. & Finidori, J. (1998) Growth-hormone-receptor and cytokine-receptor-family signaling. European Journal of Biochemistry, 255, 111.
  • Muller, M., Briscoe, J., Laxton, C., Guschin, D., Ziemiecki, A., Silvennoinen, O., Harpur, A.G., Barbieri, G., Witthuhn, B.A., Schindler, C., Pellegrini, S., Wilks, A.F., Ihle, J.N., Stark, G.M. & Kerr, I.M. (1993) The protein tyrosine kinase JAK1 complements defects in interferon-alpha/beta and -gamma signal transduction. Nature, 366, 129135.
  • Murati, A., Gelsi-Boyer, V., Adelaide, J., Perot, C., Talmant, P., Giraudier, S., Lode, L., Letessier, A., Delaval, B., Brunel, V., Imbert, M., Garand, R., Xerri, L., Birnbaum, D., Mozziconacci, M.J. & Chaffanet, M. (2005) PCM1-JAK2 fusion in myeloproliferative disorders and acute erythroid leukemia with t(8;9) translocation. Leukemia, 19, 16921696.
  • Myers, M.P., Andersen, J.N., Cheng, A., Tremblay, M.L., Horvath, C.M., Parisien, J.P., Salmeen, A., Barford, D. & Tonks, N.K. (2001) TYK2 and JAK2 are substrates of protein-tyrosine phosphatase 1B. Journal of Biological Chemistry, 276, 4777147774.
  • Nelson, M.E. & Steensma, D.P. (2006) JAK2 V617F in myeloid disorders: what do we know now, and where are we headed? Leukemia and Lymphoma, 47, 177194.
  • Nishi, M., Werner, E.D., Oh, B.C., Frantz, J.D., Dhe-Paganon, S., Hansen, L., Lee, J. & Shoelson, S.E. (2005) Kinase activation through dimerization by human SH2-B. Molecular and Cellular Biology, 25, 26072621.
  • Niwa, Y., Kanda, H., Shikauchi, Y., Saiura, A., Matsubara, K., Kitagawa, T., Yamamoto, J., Kubo, T. & Yoshikawa, H. (2005) Methylation silencing of SOCS-3 promotes cell growth and migration by enhancing JAK/STAT and FAK signalings in human hepatocellular carcinoma. Oncogene, 24, 64066417.
  • Nosaka, T., Van Deursen, J.M., Tripp, R.A., Thierfelder, W.E., Witthuhn, B.A., McMickle, A.P., Doherty, P.C., Grosveld, G.C. & Ihle, J.N. (1995) Defective lymphoid development in mice lacking Jak3. Science, 270, 800802.
  • O'Shea, J.J., Husa, M., Li, D., Hofmann, S.R., Watford, W., Roberts, J.L., Buckley, R.H., Changelian, P. & Candotti, F. (2004a) Jak3 and the pathogenesis of severe combined immunodeficiency. Molecular Immunology, 41, 727737.
  • O'Shea, J.J., Pesu, M., Borie, D.C. & Changelian, P.S. (2004b) A new modality for immunosuppression: targeting the JAK/STAT pathway. Nature Reviews Drug Discovery, 3, 555564.
  • O'Shea, J.J., Park, H., Pesu, M., Borie, D. & Changelian, P. (2005) New strategies for immunosuppression: interfering with cytokines by targeting the Jak/Stat pathway. Current Opinion in Rheumatology, 17, 305311.
  • Oka, T., Ouchida, M., Koyama, M., Ogama, Y., Takada, S., Nakatani, Y., Tanaka, T., Yoshino, T., Hayashi, K., Ohara, N., Kondo, E., Takahashi, K., Tsuchiyama, J., Tanimoto, M., Shimizu, K. & Akagi, T. (2002) Gene silencing of the tyrosine phosphatase SHP1 gene by aberrant methylation in leukemias/lymphomas. Cancer Research, 62, 63906394.
  • Parganas, E., Wang, D., Stravopodis, D., Topham, D.J., Marine, J.C., Teglund, S., Vanin, E.F., Bodner, S., Colamonici, O.R., Van Deursen, J.M., Grosveld, G. & Ihle, J.N. (1998) Jak2 is essential for signaling through a variety of cytokine receptors. Cell, 93, 385395.
  • Park, S.Y., Saijo, K., Takahashi, T., Osawa, M., Arase, H., Hirayama, N., Miyake, K., Nakauchi, H., Shirasawa, T. & Saito, T. (1995) Developmental defects of lymphoid cells in Jak3 kinase-deficient mice. Immunity, 3, 771782.
  • Park, C., Li, S., Cha, E. & Schindler, C. (2000) Immune response in Stat2 knockout mice. Immunity, 13, 795804.
  • Passamonti, F., Rumi, E., Pietra, D., Porta, M.G., Boveri, E., Pascutto, C., Vanelli, L., Arcaini, L., Burcheri, S., Malcovati, L., Lazzarino, M. & Cazzola, M. (2006) Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders. Blood, 107, 36763682.
  • Paukku, K. & Silvennoinen, O. (2004) STATs as critical mediators of signal transduction and transcription: lessons learned from STAT5. Cytokine and Growth Factor Reviews, 15, 435455.
  • Payne, S.R. & Kemp, C.J. (2005) Tumor suppressor genetics. Carcinogenesis, 26, 20312045.
  • Peeters, P., Raynaud, S.D., Cools, J., Wlodarska, I., Grosgeorge, J., Philip, P., Monpoux, F., Van Rompaey, L., Baens, M., Van den Berghe, H. & Marynen, P. (1997) Fusion of TEL, the ETS-variant gene 6 (ETV6), to the receptor-associated kinase JAK2 as a result of t(9;12) in a lymphoid and t(9;15;12) in a myeloid leukemia. Blood, 90, 25352540.
  • Pellegrini, S. & Dusanter-Fourt, I. (1997) The structure, regulation and function of the Janus kinases (JAKs) and the signal transducers and activators of transcription (STATs). European Journal of Biochemistry, 248, 615633.
  • Picard, C. & Casanova, J.L. (2004) Inherited disorders of cytokines. Current Opinion in Pediatrics, 16, 648658.
  • Radtke, S., Haan, S., Jorissen, A., Hermanns, H.M., Diefenbach, S., Smyczek, T., Schmitz-Vandeleur, H., Heinrich, P.C., Behrmann, I. & Haan, C. (2005) The Jak1 SH2 domain does not fulfill a classical SH2 function in Jak/STAT signaling but plays a structural role for receptor interaction and up-regulation of receptor surface expression. Journal of Biological Chemistry, 280, 2576025768.
  • Ragimbeau, J., Dondi, E., Alcover, A., Eid, P., Uze, G. & Pellegrini, S. (2003) The tyrosine kinase Tyk2 controls IFNAR1 cell surface expression. EMBO Journal, 22, 537547.
  • Rane, S.G. & Reddy, E.P. (2002) JAKs, STATs and Src kinases in hematopoiesis. Oncogene, 21, 33343358.
  • Reilly, J.T. (2003) Receptor tyrosine kinases in normal and malignant haematopoiesis. Blood Reviews, 17, 241248.
  • Reiter, A., Walz, C., Watmore, A., Schoch, C., Blau, I., Schlegelberger, B., Berger, U., Telford, N., Aruliah, S., Yin, J.A., Vanstraelen, D., Barker, H.F., Taylor, P.C., O'Driscoll, A., Benedetti, F., Rudolph, C., Kolb, H.J., Hochhaus, A., Hehlmann, R., Chase, A. & Cross, N.C. (2005) The t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2. Cancer Research, 65, 26622667.
  • Richter, M.F., Dumenil, G., Uze, G., Fellous, M. & Pellegrini, S. (1998) Specific contribution of Tyk2 JH regions to the binding and the expression of the interferon alpha/beta receptor component IFNAR1. Journal of Biological Chemistry, 273, 2472324729.
  • Rodig, S.J., Meraz, M.A., White, J.M., Lampe, P.A., Riley, J.K., Arthur, C.D., King, K.L., Sheehan, K.C., Yin, L., Pennica, D., Johnson, Jr, E.M. & Schreiber, R.D. (1998) Disruption of the Jak1 gene demonstrates obligatory and nonredundant roles of the Jaks in cytokine-induced biologic responses. Cell, 93, 373383.
  • Roumiantsev, S., Krause, D.S., Neumann, C.A., Dimitri, C.A., Asiedu, F., Cross, N.C. & Van Etten, R.A. (2004) Distinct stem cell myeloproliferative/T lymphoma syndromes induced by ZNF198-FGFR1 and BCR-FGFR1 fusion genes from 8p11 translocations. Cancer Cell, 5, 287298.
  • Royer, Y., Staerk, J., Costuleanu, M., Courtoy, P.J. & Constantinescu, S.N. (2005) Janus kinases affect thrombopoietin receptor cell surface localization and stability. Journal of Biological Chemistry, 280, 2725127261.
  • Saharinen, P. & Silvennoinen, O. (2002) The pseudokinase domain is required for suppression of basal activity of Jak2 and Jak3 tyrosine kinases and for cytokine-inducible activation of signal transduction. Journal of Biological Chemistry, 277, 4795447963.
  • Saharinen, P., Takaluoma, K. & Silvennoinen, O. (2000) Regulation of the Jak2 tyrosine kinase by its pseudokinase domain. Molecular and Cellular Biology, 20, 33873395.
  • Saharinen, P., Vihinen, M. & Silvennoinen, O. (2003) Autoinhibition of Jak2 tyrosine kinase is dependent on specific regions in its pseudokinase domain. Molecular Biology of the Cell, 14, 14481459.
  • Savage, K.J., Monti, S., Kutok, J.L., Cattoretti, G., Neuberg, D., De Leval, L., Kurtin, P., Dal Cin, P., Ladd, C., Feuerhake, F., Aguiar, R.C., Li, S., Salles, G., Berger, F., Jing, W., Pinkus, G.S., Habermann, T., Dalla-Favera, R., Harris, N.L., Aster, J.C., Golub, T.R. & Shipp, M.A. (2003) The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. Blood, 102, 38713879.
  • Schindler, C., Shuai, K., Prezioso, V.R. & Darnell, Jr, J.E. (1992) Interferon-dependent tyrosine phosphorylation of a latent cytoplasmic transcription factor. Science, 257, 809813.
  • Schwaller, J., Frantsve, J., Aster, J., Williams, I.R., Tomasson, M.H., Ross, T.S., Peeters, P., Van Rompaey, L., Van Etten, R.A., Ilaria, Jr, R., Marynen, P. & Gilliland, D.G. (1998) Transformation of hematopoietic cell lines to growth-factor independence and induction of a fatal myelo- and lymphoproliferative disease in mice by retrovirally transduced TEL/JAK2 fusion genes. EMBO Journal, 17, 53215333.
  • Schwaller, J., Parganas, E., Wang, D., Cain, D., Aster, J.C., Williams, I.R., Lee, C.K., Gerthner, R., Kitamura, T., Frantsve, J., Anastasiadou, E., Loh, M.L., Levy, D.E., Ihle, J.N. & Gilliland, D.G. (2000) Stat5 is essential for the myelo-and lymphoproliferative disease induced by TEL/JAK2. Molecular Cell, 6, 693704.
  • Seki, Y., Hayashi, K., Matsumoto, A., Seki, N., Tsukada, J., Ransom, J., Naka, T., Kishimoto, T., Yoshimura, A. & Kubo, M. (2002) Expression of the suppressor of cytokine signaling-5 (SOCS5) negatively regulates IL-4-dependent STAT6 activation and Th2 differentiation. Proceedings of the National Academy of Sciences of the United States of America, 99, 1300313008.
  • Shimoda, K., Van Deursen, J., Sangster, M.Y., Sarawar, S.R., Carson, R.T., Tripp, R.A., Chu, C., Quelle, F.W., Nosaka, T., Vignali, D.A., Doherty, P.C., Grosveld, G., Paul, W.E. & Ihle, J.N. (1996) Lack of IL-4-induced Th2 response and IgE class switching in mice with disrupted Stat6 gene. Nature, 380, 630633.
  • Shimoda, K., Kato, K., Aoki, K., Matsuda, T., Miyamoto, A., Shibamori, M., Yamashita, M., Numata, A., Takase, K., Kobayashi, S., Shibata, S., Asano, Y., Gondo, H., Sekiguchi, K., Nakayama, K., Nakayama, T., Okamura, T., Okamura, S. & Niho, Y. (2000) Tyk2 plays a restricted role in IFN alpha signaling, although it is required for IL-12-mediated T cell function. Immunity, 13, 561571.
  • Simoncic, P.D., Lee-Loy, A., Barber, D.L., Tremblay, M.L. & McGlade, C.J. (2002) The T cell protein tyrosine phosphatase is a negative regulator of janus family kinases 1 and 3. Current Biology, 12, 446453.
  • Staerk, J., Kallin, A., Demoulin, J.B., Vainchenker, W. & Constantinescu, S.N. (2005) JAK1 and Tyk2 activation by the homologous polycythemia vera JAK2 V617F mutation: cross-talk with IGF1 receptor. Journal of Biological Chemistry, 280, 4189341899.
  • Steensma, D.P., Dewald, G.W., Lasho, T.L., Powell, H.L., McClure, R.F., Levine, R.L., Gilliland, D.G. & Tefferi, A. (2005) The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both ‘‘atypical“ myeloproliferative disorders and myelodysplastic syndromes. Blood, 106, 12071209.
  • Steensma, D.P., McClure, R.F., Karp, J.E., Tefferi, A., Lasho, T.L., Powell, H.L., Dewald, G.W. & Kaufmann, S.H. (2006) JAK2 V617F is a rare finding in de novo acute myeloid leukemia, but STAT3 activation is common and remains unexplained. Leukemia, 20, 971978.
  • Stevenson, N.J., Haan, S., McClurg, A.E., McGrattan, M.J., Armstrong, M.A., Heinrich, P.C. & Johnston, J.A. (2004) The chemoattractants, IL-8 and formyl-methionyl-leucyl-phenylalanine, regulate granulocyte colony-stimulating factor signaling by inducing suppressor of cytokine signaling-1 expression. Journal of Immunology, 173, 32433249.
  • Stoiber, D., Kovarik, P., Cohney, S., Johnston, J.A., Steinlein, P. & Decker, T. (1999) Lipopolysaccharide induces in macrophages the synthesis of the suppressor of cytokine signaling 3 and suppresses signal transduction in response to the activating factor IFN-gamma. Journal of Immunology, 163, 26402647.
  • Stoiber, D., Kovacic, B., Schuster, C., Schellack, C., Karaghiosoff, M., Kreibich, R., Weisz, E., Artwohl, M., Kleine, O.C., Muller, M., Baumgartner-Parzer, S., Ghysdael, J., Freissmuth, M. & Sexl, V. (2004) TYK2 is a key regulator of the surveillance of B lymphoid tumors. Journal of Clinical Investigation, 114, 16501658.
  • Takeda, K., Tanaka, T., Shi, W., Matsumoto, M., Minami, M., Kashiwamura, S., Nakanishi, K., Yoshida, N., Kishimoto, T. & Akira, S. (1996) Essential role of Stat6 in IL-4 signalling. Nature, 380, 627630.
  • Takeda, K., Noguchi, K., Shi, W., Tanaka, T., Matsumoto, M., Yoshida, N., Kishimoto, T. & Akira, S. (1997) Targeted disruption of the mouse Stat3 gene leads to early embryonic lethality. Proceedings of the National Academy of Sciences of the United States of America, 94, 38013804.
  • Takemoto, S., Mulloy, J.C., Cereseto, A., Migone, T.S., Patel, B.K., Matsuoka, M., Yamaguchi, K., Takatsuki, K., Kamihira, S., White, J.D., Leonard, W.J., Waldmann, T. & Franchini, G. (1997) Proliferation of adult T cell leukemia/lymphoma cells is associated with the constitutive activation of JAK/STAT proteins. Proceedings of the National Academy of Sciences of the United States of America, 94, 1389713902.
  • Tamada, T., Honjo, E., Maeda, Y., Okamoto, T., Ishibashi, M., Tokunaga, M. & Kuroki, R. (2006) Homodimeric cross-over structure of the human granulocyte colony-stimulating factor (GCSF) receptor signaling complex. Proceedings of the National Academy of Sciences of the United States of America, 103, 31353140.
  • Tanaka, T., Soriano, M.A. & Grusby, M.J. (2005) SLIM is a nuclear ubiquitin E3 ligase that negatively regulates STAT signaling. Immunity, 22, 729736.
  • Tefferi, A. & Gilliland, D.G. (2005) JAK2 in myeloproliferative disorders is not just another kinase. Cell Cycle, 4, 10531056.
  • Tefferi, A. & Pardanani, A. (2004) Clinical, genetic, and therapeutic insights into systemic mast cell disease. Current Opinion in Hematology, 11, 5864.
  • Tefferi, A. & Pardanani, A. (2006) Mutation screening for JAK2(V617F): When to order the test and how to interpret the results. Leukemia Research, 30, 739744.
  • Tefferi, A. & Spivak, J.L. (2005) Polycythemia vera: scientific advances and current practice. Seminars in Hematology, 42, 206220.
  • Tefferi, A., Lasho, T.L., Schwager, S.M., Steensma, D.P., Mesa, R.A., Li, C.Y., Wadleigh, M. & Gary Gilliland, D. (2005a) The JAK2(V617F) tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates. British Journal of Haematology, 131, 320328.
  • Tefferi, A., Sirhan, S., Lasho, T.L., Schwager, S.M., Li, C.Y., Dingli, D., Wolanskyj, A.P., Steensma, D.P., Mesa, R. & Gilliland, D.G. (2005b) Concomitant neutrophil JAK2 mutation screening and PRV-1 expression analysis in myeloproliferative disorders and secondary polycythaemia. British Journal of Haematology, 131, 166171.
  • Tefferi, A., Lasho, T.L., Schwager, S.M., Strand, J.S., Elliott, M., Mesa, R., Li, C.Y., Wadleigh, M., Lee, S.J. & Gilliland, D.G. (2006) The clinical phenotype of wild-type, heterozygous, and homozygous JAK2V617F in polycythemia vera. Cancer, 106, 631635.
  • Teglund, S., McKay, C., Schuetz, E., Van Deursen, J.M., Stravopodis, D., Wang, D., Brown, M., Bodner, S., Grosveld, G. & Ihle, J.N. (1998) Stat5a and Stat5b proteins have essential and nonessential, or redundant, roles in cytokine responses. Cell, 93, 841850.
  • Thomis, D.C., Gurniak, C.B., Tivol, E., Sharpe, A.H. & Berg, L.J. (1995) Defects in B lymphocyte maturation and T lymphocyte activation in mice lacking Jak3. Science, 270, 794797.
  • Udy, G.B., Towers, R.P., Snell, R.G., Wilkins, R.J., Park, S.H., Ram, P.A., Waxman, D.J. & Davey, H.W. (1997) Requirement of STAT5b for sexual dimorphism of body growth rates and liver gene expression. Proceedings of the National Academy of Sciences of the United States of America, 94, 72397244.
  • Ueda, M., Ota, J., Yamashita, Y., Choi, Y.L., Ohki, R., Wada, T., Koinuma, K., Kano, Y., Ozawa, K. & Mano, H. (2003) DNA microarray analysis of stage progression mechanism in myelodysplastic syndrome. British Journal of Haematology, 123, 288296.
  • Ungureanu, D. & Silvennoinen, O. (2005) SLIM trims STATs: ubiquitin E3 ligases provide insights for specificity in the regulation of cytokine signaling. Science's STKE, 2005, pe49.
  • Ungureanu, D., Vanhatupa, S., Kotaja, N., Yang, J., Aittomaki, S., Janne, O.A., Palvimo, J.J. & Silvennoinen, O. (2003) PIAS proteins promote SUMO-1 conjugation to STAT1. Blood, 102, 33113313.
  • Ungureanu, D., Vanhatupa, S., Gronholm, J., Palvimo, J.J. & Silvennoinen, O. (2005) SUMO-1 conjugation selectively modulates STAT1-mediated gene responses. Blood, 106, 224226.
  • Vainchenker, W. & Constantinescu, S.N. (2005) A unique activating mutation in JAK2 (V617F) is at the origin of polycythemia vera and allows a new classification of myeloproliferative diseases. Hematology (American Society of Hematology Education Program), 195200. Published by the American Society of Hematology, Washington DC, USA.
  • Valentino, L. & Pierre, J. (2006) JAK/STAT signal transduction: regulators and implication in hematological malignancies. Biochemical Pharmacology, 71, 713721.
  • Vannucchi, A.M., Guglielmelli, P., Antonioli, E., Mappa, S., Pancrazzi, A., Bogani, C., Ponziani, V. & Bosi, A. (2006a) Inconsistencies in the association between the JAK2(V617F) mutation and PRV-1 over-expression among the chronic myeloproliferative diseases. British Journal of Haematology, 132, 652654; author reply 654.
  • Vannucchi, A.M., Pancrazzi, A., Bogani, C., Antonioli, E. & Guglielmelli, P. (2006b) A quantitative assay for JAK2(V617F) mutation in myeloproliferative disorders by ARMS-PCR and capillary electrophoresis. Leukemia, 20, 10551060.
  • Varinou, L., Ramsauer, K., Karaghiosoff, M., Kolbe, T., Pfeffer, K., Muller, M. & Decker, T. (2003) Phosphorylation of the Stat1 transactivation domain is required for full-fledged IFN-gamma-dependent innate immunity. Immunity, 19, 793802.
  • Velazquez, L., Fellous, M., Stark, G.R. & Pellegrini, S. (1992) A protein tyrosine kinase in the interferon alpha/beta signaling pathway. Cell, 70, 313322.
  • Vizmanos, J.L., Ormazabal, C., Larrayoz, M.J., Cross, N.C. & Calasanz, M.J. (2006) JAK2 V617F mutation in classic chronic myeloproliferative diseases: a report on a series of 349 patients. Leukemia, 20, 534535.
  • Wang, R., Cherukuri, P. & Luo, J. (2005) Activation of Stat3 sequence-specific DNA binding and transcription by p300/CREB-binding protein-mediated acetylation. Journal of Biological Chemistry, 280, 1152811534.
  • Ward, A.C., Touw, I. & Yoshimura, A. (2000) The Jak-Stat pathway in normal and perturbed hematopoiesis. Blood, 95, 1929.
  • Watanabe, D., Ezoe, S., Fujimoto, M., Kimura, A., Saito, Y., Nagai, H., Tachibana, I., Matsumura, I., Tanaka, T., Kanegane, H., Miyawaki, T., Emi, M., Kanakura, Y., Kawase, I., Naka, T. & Kishimoto, T. (2004) Suppressor of cytokine signalling-1 gene silencing in acute myeloid leukaemia and human haematopoietic cell lines. British Journal of Haematology, 126, 726735.
  • Watling, D., Guschin, D., Muller, M., Silvennoinen, O., Witthuhn, B.A., Quelle, F.W., Rogers, N.C., Schindler, C., Stark, G.R., Ihle, J.N. & Kerr, I.M. (1993) Complementation by the protein tyrosine kinase JAK2 of a mutant cell line defective in the interferon-gamma signal transduction pathway. Nature, 366, 166170.
  • Wen, Z., Zhong, Z. & Darnell, Jr, J.E. (1995) Maximal activation of transcription by Stat1 and Stat3 requires both tyrosine and serine phosphorylation. Cell, 82, 241250.
  • Weniger, M.A., Melzner, I., Menz, C.K., Wegener, S., Bucur, A.J., Dorsch, K., Mattfeldt, T., Barth, T.F. & Moller, P. (2006) Mutations of the tumor suppressor gene SOCS-1 in classical Hodgkin lymphoma are frequent and associated with nuclear phospho-STAT5 accumulation. Oncogene, 25, 26792684.
  • Wernig, G., Mercher, T., Okabe, R., Levine, R.L., Lee, B.H. & Gilliland, D.G. (2006) Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. Blood, 107, 42744281.
  • Wilks, A.F., Harpur, A.G., Kurban, R.R., Ralph, S.J., Zurcher, G. & Ziemiecki, A. (1991) Two novel protein-tyrosine kinases, each with a second phosphotransferase-related catalytic domain, define a new class of protein kinase. Molecular and Cellular Biology, 11, 20572065.
  • Willems, A.R., Schwab, M. & Tyers, M. (2004) A hitchhiker's guide to the cullin ubiquitin ligases: SCF and its kin. Biochimica et Biophysica Acta, 1695, 133170.
  • Wolanskyj, A.P., Lasho, T.L., Schwager, S.M., McClure, R.F., Wadleigh, M., Lee, S.J., Gilliland, D.G. & Tefferi, A. (2005) JAK2 mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance. British Journal of Haematology, 131, 208213.
  • Wormald, S. & Hilton, D.J. (2004) Inhibitors of cytokine signal transduction. Journal of Biological Chemistry, 279, 821824.
  • Yamamoto, K., Quelle, F.W., Thierfelder, W.E., Kreider, B.L., Gilbert, D.J., Jenkins, N.A., Copeland, N.G., Silvennoinen, O. & Ihle, J.N. (1994) Stat4, a novel gamma interferon activation site-binding protein expressed in early myeloid differentiation. Molecular and Cellular Biology, 14, 43424349.
  • Yamaoka, K., Saharinen, P., Pesu, M., Holt, III, V.E., Silvennoinen, O. & O'Shea, J.J. (2004) The Janus kinases (Jaks). Genome Biology, 5, 253.
  • Yao, Z., Cui, Y., Watford, W.T., Bream, J.H., Yamaoka, K., Hissong, B.D., Li, D., Durum, S.K., Jiang, Q., Bhandoola, A., Hennighausen, L. & O'Shea, J.J. (2006) Stat5a/b are essential for normal lymphoid development and differentiation. Proceedings of the National Academy of Sciences of the United States of America, 103, 10001005.
  • Yasukawa, H., Misawa, H., Sakamoto, H., Masuhara, M., Sasaki, A., Wakioka, T., Ohtsuka, S., Imaizumi, T., Matsuda, T., Ihle, J.N. & Yoshimura, A. (1999) The JAK-binding protein JAB inhibits Janus tyrosine kinase activity through binding in the activation loop. EMBO Journal, 18, 13091320.
  • Yoshikawa, H., Matsubara, K., Qian, G.S., Jackson, P., Groopman, J.D., Manning, J.E., Harris, C.C. & Herman, J.G. (2001) SOCS-1, a negative regulator of the JAK/STAT pathway, is silenced by methylation in human hepatocellular carcinoma and shows growth-suppression activity. Nature Genetics, 28, 2935.
  • Yoshimura, A. (2005) Negative regulation of cytokine signaling. Clinical Reviews in Allergy and Immunology, 28, 205220.
  • Yoshimura, A., Ohkubo, T., Kiguchi, T., Jenkins, N.A., Gilbert, D.J., Copeland, N.G., Hara, T. & Miyajima, A. (1995) A novel cytokine-inducible gene CIS encodes an SH2-containing protein that binds to tyrosine-phosphorylated interleukin 3 and erythropoietin receptors. EMBO Journal, 14, 28162826.
  • Yoshimura, A., Nishinakamura, H., Matsumura, Y. & Hanada, T. (2005) Negative regulation of cytokine signaling and immune responses by SOCS proteins. Arthritis Research and Therapy, 7, 100110.
  • Yu, H. & Jove, R. (2004) The STATs of cancer – new molecular targets come of age. Nature Reviews Cancer, 4, 97105.
  • Yuan, Z.L., Guan, Y.J., Chatterjee, D. & Chin, Y.E. (2005) Stat3 dimerization regulated by reversible acetylation of a single lysine residue. Science, 307, 269273.
  • Zabolotny, J.M., Bence-Hanulec, K.K., Stricker-Krongrad, A., Haj, F., Wang, Y., Minokoshi, Y., Kim, Y.B., Elmquist, J.K., Tartaglia, L.A., Kahn, B.B. & Neel, B.G. (2002) PTP1B regulates leptin signal transduction in vivo. Developmental Cell, 2, 489495.
  • Zhang, J., Somani, A.K. & Siminovitch, K.A. (2000) Roles of the SHP-1 tyrosine phosphatase in the negative regulation of cell signalling. Seminars in Immunology, 12, 361378.
  • Zhang, Q., Raghunath, P.N., Xue, L., Majewski, M., Carpentieri, D.F., Odum, N., Morris, S., Skorski, T. & Wasik, M.A. (2002) Multilevel dysregulation of STAT3 activation in anaplastic lymphoma kinase-positive T/null-cell lymphoma. Journal of Immunology, 168, 466474.
  • Zhang, Q., Wang, H.Y., Marzec, M., Raghunath, P.N., Nagasawa, T. & Wasik, M.A. (2005) STAT3- and DNA methyltransferase 1-mediated epigenetic silencing of SHP-1 tyrosine phosphatase tumor suppressor gene in malignant T lymphocytes. Proceedings of the National Academy of Sciences of the United States of America, 102, 69486953.
  • Zhao, R., Xing, S., Li, Z., Fu, X., Li, Q., Krantz, S.B. & Zhao, Z.J. (2005) Identification of an acquired JAK2 mutation in polycythemia vera. Journal of Biological Chemistry, 280, 2278822792.